<p>OmniAb, Inc.（纳斯达克代码：OABI - 获取免费报告）内部人士 Charles Berkman 于 12 月 8 日星期一出售了 8,044 股 OmniAb 股票。该股票的平均售价为 1.96 美元，总价值为 15,766.24 美元。出售后，该内部人士直接持有公司 377,071 股股票，估值约为 739,059.16 美元。此次交易使其持股比例减少了 2.09%。该交易已在向美国证券交易委员会（SEC）提交的法律文件中披露，相关信息可通过 SEC 网站访问。</p>
<h2>OmniAb 价格表现</h2>
<p>纳斯达克 OABI 的股票在星期二开盘价为 1.99 美元。该公司的市值为 2.8648 亿美元，市盈率为-3.43，贝塔值为 0.13。该股票的 50 日移动平均价格为 1.65 美元，200 日移动平均价格为 1.71 美元。OmniAb, Inc.的年内最低价为 1.22 美元，最高价为 4.17 美元。</p>
<p>OmniAb（纳斯达克：OABI - 获取免费报告）最近一次发布财报是在 11 月 4 日星期二。公司报告本季度每股收益为（0.14）美元，超出分析师一致预期的（0.15）美元，超出幅度为 0.01 美元。OmniAb 的股本回报率为负的 23.14%，净利润率为负的 301.83%。该公司本季度的收入为 224 万美元，而一致预期为 564 万美元。平均而言，股票分析师预计 OmniAb, Inc.在当前财政年度的每股收益为-0.61 美元。</p>
<h2>对 OmniAb 的对冲基金看法</h2>
<p>对冲基金最近买入和卖出了该公司的股票。制造商人寿保险公司在第二季度将其在 OmniAb 的持股比例提高了 20.5%。制造商人寿保险公司现在持有 44,809 股公司股票，价值 78,000 美元，此前在上个季度又购买了 7,624 股。Murchinson Ltd.在第一季度将其在 OmniAb 的持股比例提高了 0.8%。Murchinson Ltd.现在持有 1,007,810 股公司股票，价值 2,419,000 美元，此前在上个季度又收购了 7,810 股。Rhumbline Advisers 在第二季度将其在 OmniAb 的持股比例提高了 6.0%。Rhumbline Advisers 现在持有 160,728 股公司股票，价值 280,000 美元，此前在上个季度又收购了 9,163 股。Osaic Holdings Inc.在第二季度将其在 OmniAb 的持股比例提高了 214.4%。Osaic Holdings Inc.现在持有 14,247 股公司股票，价值 25,000 美元，此前在上个季度又购买了 9,716 股。最后，AQR Capital Management LLC 在第一季度收购了 OmniAb 的新头寸，价值约为 25,000 美元。72.08% 的股票由机构投资者持有。</p>
<h2>华尔街分析师预测增长</h2>
<p>另外，Weiss Ratings 在 12 月 1 日星期一的报告中重新发布了对 OmniAb 股票的 “卖出（d-）” 评级。三位投资分析师对该股票给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat 的数据，该公司的共识评级为 “适度买入”，共识目标价为 6.67 美元。</p>
<p><strong>查看我们对 OmniAb 的最新分析</strong></p>
<h2>关于 OmniAb</h2>
<p>（获取免费报告）</p>
<p>OmniAb, Inc.是一家生物技术公司，专注于在美国发现和提供治疗性抗体发现技术。该公司的技术平台创建并筛选多样化的抗体库，并为合作伙伴的药物开发工作识别最佳抗体。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票比 OmniAb 更好</li>
<li>上海证券交易所综合指数是什么？</li>
<li>为什么这三只汽车和工业芯片股票刚刚飙升</li>
<li>什么是分红成就者？简介</li>
<li>根据 MarketBeat，评级最高的五只分红股票</li>
<li>投资者如何识别并成功交易缺口下跌股票</li>
<li>Dollar Tree 的激增和 Home Depot 的下滑对消费者健康的影响</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0FCSQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0FCSQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 OmniAb 吗？</h2>
<p>在你考虑 OmniAb 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街评级最高和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买...而 OmniAb 并不在名单上。</p>
<p>虽然 OmniAb 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

OABI

<p>OmniAb, Inc. 的内部人士 Charles Berkman 以每股 1.96 美元的价格出售了 8,044 股，总计 15,766.24 美元。出售后，Berkman 拥有 377,071 股，持股比例减少了 2.09%。该交易已在 SEC 文件中披露。OmniAb 的股票开盘价为 1.99 美元，市值为 2.8648 亿美元。分析师对该公司的共识评级为 “适度买入”，目标价格为 6.67 美元。该公司报告第三季度每股亏损 0.14 美元，略好于预期</p>

<p>OmniAb, Inc. (NASDAQ:OABI - Get Free Report) insider Charles Berkman sold 8,044 shares of OmniAb stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $1.96, for a total value of $15,766.24. Following the sale, the insider directly owned 377,071 shares of the company's stock, valued at approximately $739,059.16. The trade was a 2.09% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.</p>
<div class="lb-trans"><p>OmniAb, Inc.（纳斯达克代码：OABI - 获取免费报告）内部人士 Charles Berkman 于 12 月 8 日星期一出售了 8,044 股 OmniAb 股票。该股票的平均售价为 1.96 美元，总价值为 15,766.24 美元。出售后，该内部人士直接持有公司 377,071 股股票，估值约为 739,059.16 美元。此次交易使其持股比例减少了 2.09%。该交易已在向美国证券交易委员会（SEC）提交的法律文件中披露，相关信息可通过 SEC 网站访问。</p>
</div><h2>OmniAb Price Performance</h2>
<div class="lb-trans"><h2>OmniAb 价格表现</h2>
</div><p>Shares of NASDAQ OABI opened at $1.99 on Tuesday. The firm has a market cap of $286.48 million, a price-to-earnings ratio of -3.43 and a beta of 0.13. The stock's fifty day moving average price is $1.65 and its two-hundred day moving average price is $1.71. OmniAb, Inc. has a one year low of $1.22 and a one year high of $4.17.</p>
<div class="lb-trans"><p>纳斯达克 OABI 的股票在星期二开盘价为 1.99 美元。该公司的市值为 2.8648 亿美元，市盈率为-3.43，贝塔值为 0.13。该股票的 50 日移动平均价格为 1.65 美元，200 日移动平均价格为 1.71 美元。OmniAb, Inc.的年内最低价为 1.22 美元，最高价为 4.17 美元。</p>
</div><p>OmniAb (NASDAQ:OABI - Get Free Report) last posted its earnings results on Tuesday, November 4th. The company reported ($0.14) earnings per share for the quarter, topping analysts' consensus estimates of ($0.15) by $0.01. OmniAb had a negative return on equity of 23.14% and a negative net margin of 301.83%.The company had revenue of $2.24 million during the quarter, compared to the consensus estimate of $5.64 million. On average, equities analysts anticipate that OmniAb, Inc. will post -0.61 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>OmniAb（纳斯达克：OABI - 获取免费报告）最近一次发布财报是在 11 月 4 日星期二。公司报告本季度每股收益为（0.14）美元，超出分析师一致预期的（0.15）美元，超出幅度为 0.01 美元。OmniAb 的股本回报率为负的 23.14%，净利润率为负的 301.83%。该公司本季度的收入为 224 万美元，而一致预期为 564 万美元。平均而言，股票分析师预计 OmniAb, Inc.在当前财政年度的每股收益为-0.61 美元。</p>
</div><h2>Hedge Funds Weigh In On OmniAb</h2>
<div class="lb-trans"><h2>对 OmniAb 的对冲基金看法</h2>
</div><p>Hedge funds have recently bought and sold shares of the company. The Manufacturers Life Insurance Company raised its position in shares of OmniAb by 20.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 44,809 shares of the company's stock valued at $78,000 after buying an additional 7,624 shares in the last quarter. Murchinson Ltd. boosted its position in shares of OmniAb by 0.8% during the 1st quarter. Murchinson Ltd. now owns 1,007,810 shares of the company's stock worth $2,419,000 after acquiring an additional 7,810 shares in the last quarter. Rhumbline Advisers increased its stake in OmniAb by 6.0% in the second quarter. Rhumbline Advisers now owns 160,728 shares of the company's stock valued at $280,000 after acquiring an additional 9,163 shares during the last quarter. Osaic Holdings Inc. raised its position in OmniAb by 214.4% during the second quarter. Osaic Holdings Inc. now owns 14,247 shares of the company's stock valued at $25,000 after purchasing an additional 9,716 shares in the last quarter. Finally, AQR Capital Management LLC acquired a new position in OmniAb during the first quarter valued at approximately $25,000. 72.08% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>对冲基金最近买入和卖出了该公司的股票。制造商人寿保险公司在第二季度将其在 OmniAb 的持股比例提高了 20.5%。制造商人寿保险公司现在持有 44,809 股公司股票，价值 78,000 美元，此前在上个季度又购买了 7,624 股。Murchinson Ltd.在第一季度将其在 OmniAb 的持股比例提高了 0.8%。Murchinson Ltd.现在持有 1,007,810 股公司股票，价值 2,419,000 美元，此前在上个季度又收购了 7,810 股。Rhumbline Advisers 在第二季度将其在 OmniAb 的持股比例提高了 6.0%。Rhumbline Advisers 现在持有 160,728 股公司股票，价值 280,000 美元，此前在上个季度又收购了 9,163 股。Osaic Holdings Inc.在第二季度将其在 OmniAb 的持股比例提高了 214.4%。Osaic Holdings Inc.现在持有 14,247 股公司股票，价值 25,000 美元，此前在上个季度又购买了 9,716 股。最后，AQR Capital Management LLC 在第一季度收购了 OmniAb 的新头寸，价值约为 25,000 美元。72.08% 的股票由机构投资者持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Separately, Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of OmniAb in a report on Monday, December 1st. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $6.67.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 12 月 1 日星期一的报告中重新发布了对 OmniAb 股票的 “卖出（d-）” 评级。三位投资分析师对该股票给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat 的数据，该公司的共识评级为 “适度买入”，共识目标价为 6.67 美元。</p>
</div><p><strong>View Our Latest Analysis on OmniAb</strong></p>
<div class="lb-trans"><p><strong>查看我们对 OmniAb 的最新分析</strong></p>
</div><h2>About OmniAb</h2>
<div class="lb-trans"><h2>关于 OmniAb</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.</p>
<div class="lb-trans"><p>OmniAb, Inc.是一家生物技术公司，专注于在美国发现和提供治疗性抗体发现技术。该公司的技术平台创建并筛选多样化的抗体库，并为合作伙伴的药物开发工作识别最佳抗体。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than OmniAb</li>
<li>What is the Shanghai Stock Exchange Composite Index?</li>
<li>Why These 3 Automotive &amp; Industrial Chip Stocks Just Soared</li>
<li>What Are Dividend Achievers? An Introduction</li>
<li>Top 5 Highest-Rated Dividend Stocks, According to MarketBeat</li>
<li>How Investors Can Identify and Successfully Trade Gap-Down Stocks</li>
<li>What Dollar Tree’s Surge and Home Depot’s Slide Say About Consumer Health</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 OmniAb 更好</li>
<li>上海证券交易所综合指数是什么？</li>
<li>为什么这三只汽车和工业芯片股票刚刚飙升</li>
<li>什么是分红成就者？简介</li>
<li>根据 MarketBeat，评级最高的五只分红股票</li>
<li>投资者如何识别并成功交易缺口下跌股票</li>
<li>Dollar Tree 的激增和 Home Depot 的下滑对消费者健康的影响</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0FCSQ" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=OABI"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in OmniAb Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 OmniAb 吗？</h2>
</div><p>Before you consider OmniAb, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 OmniAb 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OmniAb wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街评级最高和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买...而 OmniAb 并不在名单上。</p>
</div><p>While OmniAb currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 OmniAb 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

OmniAb (NASDAQ:OABI) 内部人士 Charles Berkman 出售了 8,044 股股票